ArticleCurrent sleep medicine reports2025
Sleep and circadian effects on the incretin system.
Article in Current sleep medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Microbiota-Gut-Brain Axis in Insomnia: Mechanisms and Intervention Strategies.Life (Basel, Switzerland) · 2026Review
- Chronopharmacology-Driven Precision Therapies for Time-Optimized Cardiometabolic Disease Management.Biology · 2026Review
- Impaired Brain Incretin and Gut Hormone Expression in Human Alcohol-Related Brain Damage: Opportunities for Therapeutic Targeting.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Purpose of review: Little is known about how incretins interact with sleep and circadian factors, both of which influence metabolic outcomes. We review evidence that sleep, circadian rhythms, and their disturbances impact incretin secretion and discuss clinical applications for GLP-1/GIP-RA drugs in sleep medicine and areas for future research. Recent Findings: GLP-1 secretion exhibits a circadian rhythm which may be disrupted by high-fat diet, meal timing, and gut dysbiosis. Insufficient sleep may alter the timing of postprandial GLP-1 release, and the circadian rhythm of GLP-1 secretion is blunted in patients with metabolic conditions such as obesity or diabetes. Lastly, the FDA has approved the use of tirzepatide (a GLP-1/GIP-RA drug) for treating obstructive sleep apnea. Summary: Evidence suggests that sleep and circadian rhythms impact the incretin system, although findings are somewhat mixed due to the variety of methods employed. In light of the growing interest in new clinical applications for incretin therapies, more research is needed to fully understand the relationship between sleep, circadian rhythms, and incretin secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.